Condition category
Nutritional, Metabolic, Endocrine
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
The menopause happens when a woman stops having periods and is no longer able to get pregnant naturally. Symptoms can include hot flushes, low mood or anxiety, reduced sex drive and problems with memory and concentration. It can also increase the risk of developing osteoporosis, a condition where the bones become weaker and more likely to break. This study investigates whether a food supplement can alleviate the symptoms of the menopause and reduce the likelihood of developing osteoporosis.

Who can participate?
Women aged between 50-55 and going through the menopause.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in group 1 are given the active food supplement. Those in group 2 are given a placebo (dummy pill). Markers that show whether the participant is at risk of developing osteoporosis are measured for all participats before treatment begins, 6 months after treatment and again after 12 months.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Farcoderm Srl, San Martino Siccomario (Italy)

When is the study starting and how long is it expected to run for?
April 2011 to May 2012

Who is funding the study?
Paladin Pharma S.p.A.

Who is the main contact?
Dr Nobile Vincenzo

Trial website

Contact information



Primary contact

Dr Nobile Vincenzo


Contact details

Via Mons. Angelini
San Martino Siccomario
0039 0382 25504

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Assessment of the efficacy of a food supplement in improving bone turnover markers and menopause-related symptoms in post-menopausal women: a double blind, randomized clinical study of efficacy and safety.


Study hypothesis

The study is aimed to assess the efficacy of the product in modulating the bone turnover markers and in improving the menopause-related symptoms in post-menopausal women.

Ethics approval

Independent Ethical Committee for Non-Pharmacological Clinical trials’, 30/03/2011, ref: 2011/02).

Study design

Monocentric, randomized, parallel group, interventional study

Primary study design


Secondary study design

Randomised parallel trial

Trial setting


Trial type

Quality of life

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet.


Menopause and bone turnover


Treatment allocation is randomized according to a computer generated restricted randomization list.
The active product was named “Integratore menopausa Lot. FH226” while the placebo product was named “Integratore menopausa Lot. FH314”. The active and the placebo products were in tablet form and identical in appearance.

Product efficacy in modulating bone turnover markers was evaluated in 60 subjects (30 subjects per treatment arm) before and after 6 and 12 months treatment. The following markers were measured: deoxypyridinoline (DPD), acid phosphatase (AP), osteocalcin (OC), and bone-specific alkaline phosphatase (BAP). Bone mineral density (BMD) was assessed in a sub-group (n=15) of subjects. Product efficacy on ameliorating menopausal symptomatology was assessed in 60 subjects (30 subjects per treatment arm) before and after 1 and 3 months treatment by means of a validated questionnaire.

Intervention type



Drug names

Primary outcome measures

1. Urinary Deoxypyridinoline (DPD) measured by means of high-performance liquid cromatography (HPLC), at baseline, and then 6 months and 12 months after treatment
2. Serum Acid phosphatase (AP) measured by means of electrophoresis on agarose gel according to the optimized method by D.G.K.C. at 37°C, at baseline, and then 6 months and 12 months after treatment
3. Serum Osteocalcin (OC) measured by means of electrochemiluminescence technique (ECLIA), at baseline, and then 6 months and 12 months after treatment
4. Serum Bone-specific alkaline phosphatase (BAP) measured by means of colorimetric-enzymatic technique, at baseline, and then 6 months and 12 months after treatment
5. Menopause syndrome by means of Menopause Rating Scale, assessed at baseline, 1 month and 3 months after treatment

Secondary outcome measures

1. Bone mineral density (BMD), measured at baseline, and then 6 months and 12 months after treatment
2. Amelioration of depression associated to menopause
3. Amelioration of sleep

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Healthy female subjects; Age: between 50 and 55 years old
2. Caucasian ethnicity
3. Body mass index between 20 and 25
4. Slightly overweight (10-20% than ideal weight)
5. Menopause onset (date of last menstrual cycle) not longer than 1 year from the date of study entry
6. Case history characterized by menopausal syndrome psychological complaints (anxiety, emotional instability, depression), hot flush, localized fat and body fat percentage increase
7. No participation in similar trials
8. Absence of disease
9. Agreement not to make any changes to the normal everyday routine
10. Agreement not to use during the study products with activity similar such than the tested product
11. Agreement not to make any changes to eating habits
12. Subjects informed of the trial procedures who have signed an informed consent form

Participant type

Healthy volunteer

Age group




Target number of participants


Participant exclusion criteria

1. Subjects not satisfying the inclusion criteria
2. Subjects under local or systemic pharmacological treatment
3. Subjects who do not have endometrial hyperplasia in their case history
4. Hormone replacement therapy
5. Metabolic syndrome
6. Depressive syndrome not menopause related
7. Subjects with food intolerances

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Farcoderm Srl
Via Mons. Angelini. 21
San Martino Siccomario

Sponsor information


Paladin Pharma S.p.A.

Sponsor details

Via Vincenzo Monti

Sponsor type




Funder type


Funder name

Paladin Pharma S.p.A.

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Data (all the study data) will be published in an appropriate scientific journal in the field of menopause. The manuscript is under drafting and is planned to be submitted to the identified scientific journal by May 2016.

Intention to publish date


Participant level data

Not expected to be available

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes